TERN (ternspharma.com) Market Value to Book Value Ratio

Terns Pharmaceuticals (TERN) is a biotech startup whose financial stability relies on external grants and strategic alliances until its products reach the market. The business generates revenue through the development of oral treatments for obesity and liver pathologies, with the indicator standing at 5.90. This historical price chart clearly demonstrates the asset's dynamics. However, high testing costs and fierce competition create significant clinical threats.

To filter investment risks, it is essential to assess the gap between the market price and the actual net asset value. This metric is calculated as the ratio of market capitalization to equity, and changes in the market-to-book ratio help determine the degree of overvaluation for Terns Pharmaceuticals (TERN), whose value is based on the development potential of obesity drugs and employee RSU incentives.